A handful of CDMOs have made changes at the top over the past few weeks, including Genezen and Curia.
That also includes Australian CDMO BioCina, which announced last week that Mark Womack would be taking the helm. Womack previously served as chief business officer at AGC Biologics, CEO of Indian manufacturer Stelis Biopharma and most recently, CEO at CDMO KBI Biopharma and Selexis SA.
BioCina completed the takeover of a Pfizer manufacturing facility in Adelaide in 2021 and is now prepping for wider growth. Endpoints News sat down with Womack to discuss his new role, plans for the future, and how to compete in the wider CDMO market. This interview has been edited for brevity and clarity.
Endpoints: What made you want to take the CEO role at BioCina?
Womack: The most satisfying thing in my career today was being able to help build out AGC Biologics from what…
Click here to view original post